Solasia Pharma KK
TSE:4597
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
27
46
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| JP |
|
Solasia Pharma KK
TSE:4597
|
7.8B JPY |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
385B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.4B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
169B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.3B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.1B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.2B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.8B USD |
Loading...
|
Market Distribution
| Min | -125 500% |
| 30th Percentile | 4.2% |
| Median | 7% |
| 70th Percentile | 10.6% |
| Max | 9 743.7% |
Other Profitability Ratios
Solasia Pharma KK
Glance View
Solasia Pharma KK engages in the development, sale, import and export of pharmaceutical products and medical devices. The company is headquartered in Minato-Ku, Tokyo-To and currently employs 77 full-time employees. The company went IPO on 2017-03-24. is a Japan-based pharmaceutical company. The firm is mainly engaged in the development, sale, importing and exporting of pharmaceutical products targeting commercialization in Japan, China and other Asian countries. The company focuses on commercializing assets in the oncology/hematology field, by developing products licensed from western pharmaceutical and biotech companies. The firm's main products include SP-01 Granisetron Transdermal Delivery System (Sancuso), SP-02 Darinaparsin (Zinapar, ZIO-101, and SP-03 Oral Medical Device (episil oral liquid).
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Solasia Pharma KK is -543.6%, which is below its 3-year median of -468%.
Over the last 3 years, Solasia Pharma KK’s Operating Margin has decreased from -303.6% to -543.6%. During this period, it reached a low of -1 308.4% on Sep 30, 2024 and a high of -107.9% on Sep 30, 2023.